INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.75
+4.17%Next report
Analyst consensus
- Next report date
- Feb 16, 2027
- EPS estimate
- -$135
- Revenue estimate
- $300.0K
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- -$0.36
- EPS estimate
- -$94
- Revenue actual
- —
- Revenue estimate
- $300.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +96.0%
- Revenue beats (12Q)
- 1
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$94 | -$0.36 | Beat 99.62% | — |
| Sep 23, 2026 | -$94 | -$1.43 | Beat 98.49% | $2.1B |
| May 6, 2026 | -$94 | -$0.69 | Beat 99.27% | — |
| Feb 11, 2026 | — | -$513.0K | — | $820.2M |
| Nov 6, 2025 | — | -$0.44 | — | $1.1M |
| Sep 23, 2025 | — | -$3.80 | — | $1.8M |
| Feb 12, 2025 | — | -$3.64 | — | $772.5M |
| Nov 14, 2024 | — | -$54 | — | $936.2K |
| Sep 27, 2024 | — | -$3.80 | — | $938.5K |
| Feb 13, 2024 | — | -$3.80 | — | $933.8K |
| Nov 14, 2023 | — | -$15 | — | $1.2M |
| May 15, 2023 | -$90 | -$12 | Beat 86.67% | $764.1K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 16, 2027